NEW: No-Cost StreetSmart Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Biota Pharmaceuticals


Biota Pharmaceuticals Inc. is focused on the discovery and development of products to treat serious viral respiratory infectious diseases. The company has two late-stage product candidates: vapendavir, a potent, broad-spectrum capsid inhibitor of enteroviruses for the treatment of human rhinovirus-infected patients with underlying respiratory illnesses, such as moderate to severe asthma and chronic obstructive pulmonary disease; and laninamivir octanoate, which is a one-time, inhaled treatment for influenza A and B infections. Biota has also completed IND-enabling studies for BTA-C585, an orally bioavailable F-protein inhibitor in development for the treatment of respiratory syncytial virus infections and anticipates initiating clinical trials of BTA-C585 in Q3/15.